Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $9,089,637.72 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 41,124 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $221.03, for a total transaction of $9,089,637.72. Following the completion of the sale, the chief executive officer owned 108,743 shares in the company, valued at $24,035,465.29. The trade was a 27.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Leonard Chapman also recently made the following trade(s):

• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.
• On Monday, April 27th, Steven Leonard Chapman sold 5,838 shares of Natera stock. The shares were sold at an average price of $204.14, for a total value of $1,191,769.32.
• On Tuesday, March 10th, Steven Leonard Chapman sold 5,623 shares of Natera stock. The shares were sold at an average price of $204.13, for a total value of $1,147,822.99.

Natera Stock Performance

Shares of NTRA opened at $215.31 on Monday. The business’s 50-day moving average price is $204.19 and its 200 day moving average price is $216.13. The stock has a market capitalization of $30.83 billion, a P/E ratio of -132.09 and a beta of 1.56. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $256.36.

Institutional Trading of Natera

Several large investors have recently made changes to their positions in the stock. Robinhood Asset Management LLC bought a new position in shares of Natera in the fourth quarter valued at about $12,981,000. JPMorgan Chase & Co. grew its holdings in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares during the last quarter. Krilogy Financial LLC bought a new stake in Natera during the 3rd quarter worth about $1,323,000. Zweig DiMenna Associates LLC increased its position in Natera by 6.8% in the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company’s stock valued at $21,329,000 after acquiring an additional 8,400 shares in the last quarter. Finally, Systrade AG acquired a new stake in Natera in the 4th quarter valued at about $11,454,000. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

NTRA has been the subject of several recent analyst reports. Robert W. Baird set a $265.00 target price on Natera in a research report on Friday, May 8th. William Blair initiated coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating on the stock. Wolfe Research began coverage on Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 price objective for the company. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $249.00 target price on shares of Natera in a report on Tuesday, May 12th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $256.12.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.